Annals of Surgical Oncology

, Volume 25, Supplement 3, pp 938–939 | Cite as

ASO Author Reflections: Chemoradiation for High-Risk Soft Tissue Sarcomas

  • Eric Lu
  • Christopher W. RyanEmail author
ASO Author Reflections



The authors have no conflicts of interest to disclose.


  1. 1.
    Ryan CW, Montag AG, Hosenpud JR, et al. Histologic response of dose-intense chemotherapy with preoperative hypofractionated radiotherapy for patients with high-risk soft tissue sarcomas. Cancer. 2008;112(11):2432–9. Scholar
  2. 2.
    Lu E, Perlewitz KS, Hayden JB, et al. Epirubicin and ifosfamide with preoperative radiation for high-risk soft tissue sarcomas. Ann Surg Oncol. 2018;25:920–7. Scholar
  3. 3.
    Eilber FC, Rosen G, Eckardt J, et al. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol. 2001;19(13):3203–9.CrossRefGoogle Scholar
  4. 4.
    Meyer JM, Perlewitz KS, Hayden JB, et al. Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates. Clin Cancer Res. 2013;19(24):6902–11. Scholar
  5. 5.
    Pasquali S, Pizzamiglio S, Touati N, et al. Prognostic stratification using the nomogram sarculator and its impact on study results in a randomized controlled trial (RCT) for localized soft tissue sarcomas (STS): a secondary analysis of the EORTC-STBSG 62931. J Clin Oncol. 2018;36(suppl:abstr):11518. Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  1. 1.Division of Hematology and Medical Oncology, Knight Cancer InstituteOregon Health and Science UniversityPortlandUSA

Personalised recommendations